Stock listing

TASE:XTLB XTL Biopharmaceuticals Ltd. מניה‎

Home listing (TASE) of XTL Biopharmaceuticals Ltd.

Follow XTL Biopharmaceuticals Ltd. into a list and get an email when it puts out news.

Share price · TASE:XTLB

1.30 ILA (agorot) -0.10 (-7.1%)

Close on Nov 19, 2026

Past year -58.1% · daily closes, Nov 19, 2025 – Nov 19, 2026, adjusted for splits
Day range
1.30 – 1.30 ILA (agorot)Nov 19, 2026
Volume
936,830 sharesNov 19, 2026
Market cap
12.78M ILSAt the close on Nov 19, 2026 · price × 983.0M shares outstanding
52-week range
1.30 – 4.40 ILA (agorot)Lowest and highest trades, Nov 20, 2025 – Nov 19, 2026
Traded on an average day
13,292 ILSMedian day 458,672 shares · 8 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026
XTL Biopharmaceuticals Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
TASE:XTLB · Home1.30 ILA (agorot)-0.10 (-7.1%)936,8301.301.301.301.40Close on Nov 19, 2026
NASDAQ:XTLB$1.37 USD-0.11 (-7.4%)1,780$1.585$1.585$1.37$1.48Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 19, 2026 – Nov 19, 2026 · TASE:XTLB · ILA (agorot), adjusted for splits

DayCloseChange%OpenHighLowVolume
1.30-0.10-7.1%1.301.301.30936,830
1.40+0.10+7.7%1.401.401.401,011,071
1.30-0.10-7.1%1.401.401.301,661,665
1.40+0.10+7.7%1.401.401.40702,866
1.300.000.0%1.301.301.301,000,001
1.300.000.0%1.301.301.301,663,184
1.30-0.10-7.1%1.301.301.300
1.400.000.0%1.301.401.30820,000
1.400.000.0%1.401.401.40374,284
1.400.000.0%1.401.501.40479,884
1.400.000.0%1.401.401.401,748,687
1.400.000.0%1.401.401.400
1.400.000.0%1.401.401.40200,000
1.400.000.0%1.501.501.40778,000
1.400.000.0%1.401.501.40458,200
1.40-0.10-6.7%1.401.401.401,796,138
1.500.000.0%1.501.501.5021,000
1.50+0.10+7.1%1.401.501.40377,202
1.40-0.10-6.7%1.501.601.403,159,216
1.500.000.0%1.501.501.5079,600
1.50-0.10-6.3%1.601.601.50103,766
1.60+0.10+6.7%1.501.601.50443,736
1.500.000.0%1.501.501.50340,500
1.50-0.10-6.3%1.601.601.501,537,736
1.600.000.0%1.601.601.6056,073
1.600.000.0%1.601.601.6073
1.600.000.0%1.601.601.60225,000
1.60+0.10+6.7%1.601.601.600
1.50-0.10-6.3%1.601.701.501,285,548
1.60-0.20-11.1%1.701.801.603,520,742
1.800.000.0%1.801.801.702,228,534
1.800.000.0%1.901.901.80927,528
1.800.000.0%1.801.901.80776,000
1.80-0.10-5.3%1.801.801.80459,143
1.900.000.0%1.901.901.80527
1.900.000.0%1.901.901.900
1.90+0.10+5.6%1.802.001.80120,000
1.800.000.0%1.801.801.800
1.800.000.0%1.801.901.80625,625
1.80-0.10-5.3%1.901.901.80679,452
1.90+0.10+5.6%1.901.901.90252,631
1.800.000.0%1.801.801.800
1.80-0.10-5.3%1.801.801.80119,048
1.900.000.0%1.901.901.900
1.90+0.10+5.6%1.901.901.900
1.80-0.10-5.3%1.901.901.80255,855
1.90+0.10+5.6%1.901.901.90465,657
1.80-0.10-5.3%1.901.901.80631,533
1.900.000.0%1.902.001.9032,000
1.900.000.0%1.902.001.80683,470
1.900.000.0%1.901.901.90368,420
1.900.000.0%1.901.901.90158,095
1.900.000.0%1.901.901.9052,832
1.900.000.0%2.002.001.901,240,183
1.90-0.10-5.0%1.901.901.901,309,052
2.000.000.0%2.002.001.90538,500
2.000.000.0%2.002.002.00261,500
2.00-0.10-4.8%2.102.102.00588,800
2.10+0.10+5.0%2.102.102.10664,406
2.000.000.0%2.102.102.009,613,664

Splits

1 split · TASE:XTLB · every price before a split is adjusted for it

DayRatioWhat
1-for-5Consolidation
Ticker
TASE:XTLB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
TASE
Currency
ILA

What changed lately

Latest news

All XTL Biopharmaceuticals Ltd. news

XTL Biopharmaceuticals Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
8 in the last 12 months · 9 in all · newest Apr 29, 2026 · oldest 2025
Decks
9 decks · latest Nov 8, 2018

Where XTL Biopharmaceuticals Ltd. is listed

ListingExchangeCountryCurrency
TASE:XTLB · Home listing · This pageTASEIsraelILA
NASDAQ:XTLBNASDAQUnited StatesUSD
BOATS:XTLBBOATSUnited StatesUSD
gettex:HHB0gettexGermanyEUR
Munich:HHB0MunichGermanyEUR
Frankfurt:HHB0FrankfurtGermanyEUR
Lang & Schwarz:A41X7JLang & SchwarzGermanyEUR
LS Exchange:A41X7JLS ExchangeGermanyEUR
Stuttgart:HHB0StuttgartGermanyEUR

Team and board

Officers

OfficerRole
Doron TurgemanChief Executive Officer
Joshua LevineChief Executive Officer
Shlomo ShalevChief Executive Officer
Itay WeinsteinChief Financial Officer

Board

DirectorRole
Shlomo ShalevChief Executive Officer
Dobroslav MelamedDirector
Doron TurgemanChief Executive Officer
Iris Shapira YalonDirector
Jonathan SchapiroDirector
Ossi Hillel FainDirector

Decks

DeckKindSlidesDate
Investor Presentation (November 2018)Investor deck13 slidesNov 8, 2018
Investor Presentation (January 2017)Investor deck27 slidesJanuary 2017
Investor Presentation (November 2015)Investor deck20 slidesNovember 2015
Investor Presentation (September 2015)Investor deck20 slidesSep 10, 2015
Investor Presentation (June 2015)Investor deck28 slidesJune 2015
Investor Presentation (May 2015)Investor deck25 slidesMay 2015
Investor Presentation (December 2014)Investor deck26 slidesDecember 2014
IPO Roadshow (September 2014)IPO roadshow31 slidesSep 26, 2014
Investor Presentation (January 2014)Investor deck48 slidesJanuary 2014

Open Decks

Financings

RaiseDate
Private placement
Announced: up to US$2M
Use of proceeds: Together with the NeuroNOS acquisition, to remedy the Nasdaq minimum stockholders' equity deficiency
Jan 29, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue451.0K
Cost of revenue448.0K
Gross profit3.00K
Research and development98.0K31.0K30.0K30.0K38.0K35.0K38.0K43.0K443.0K578.0K
Operating income-2.17M-765.0K-880.0K-1.03M-948.0K-842.0K-793.0K-1.25M-2.56M-3.61M
Depreciation and amortization199.0K1.00K1.00K1.00K1.00K3.00K7.00K
EBITDA-1.97M-879.0K-1.03M-947.0K-1.25M-2.56M-3.60M
Interest expense28.0K1.56M21.0K2.19M603.0K35.0K337.0K7.00K15.0K
Income before tax-1.16M-1.78M-1.35M
Income tax-130.0K
Net income-1.03M-1.78M-1.35M435.0K-2.95M-763.0K3.63M-781.0K-2.54M2.00K
Earnings per share, basic-0.00-0.00-0.000.00-0.01-0.000.01-0.00-0.01
Earnings per share, diluted-0.00-0.00-0.000.00-0.01-0.00

Balance sheet

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash and equivalents371.0K1.40M2.09M2.97M3.63M4.46M3.25M3.29M2.02M3.82M
Short-term investments1.63M3.16M2.41M
Receivables99.0K
Current assets1.34M2.05M3.81M6.24M6.12M6.83M8.20M6.21M2.75M
Property, plant and equipment187.0K10.0K
Goodwill3.19M
Total assets8.55M2.43M4.19M6.62M6.50M7.21M8.57M6.59M3.02M
Accounts payable790.0K206.0K187.0K231.0K254.0K232.0K253.0K300.0K17.0K
Current liabilities2.21M206.0K300.0K330.0K
Total debt138.0K
Shareholders' equity5.43M2.22M4.00M5.33M3.61M6.51M7.27M3.62M2.69M4.89M
Shares outstanding881.4M544.9M544.9M544.9M514.2M514.2M514.2M514.2M274.2M

Cash flow

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations-1.62M-707.0K-901.0K-1.05M-850.0K-908.0K-816.0K-1.13M-1.73M-1.86M
Capital spending-54.0K-1.00K-2.00K-2.00K-2.00K
Free cash flow-1.67M-851.0K-910.0K-1.73M-1.86M
Cash from investing-844.0K41.0K36.0K8.00K32.0K2.11M778.0K-2.50M-66.0K-110.0K
Cash from financing1.45M385.0K4.89M3.58M
Change in cash-1.01M-666.0K-865.0K-656.0K-818.0K1.20M-38.0K1.27M-1.80M1.61M

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 20, 2026Current reportSEC
6-K · Report of a foreign issuerNov 18, 2026Current reportSEC
6-K · Report of a foreign issuerOct 14, 2026Current reportSEC
6-K · Report of a foreign issuerAug 5, 2026Current reportSEC
6-K · Report of a foreign issuerJul 21, 2026Current reportSEC
20-F · Annual reportJun 30, 2026Annual reportSEC
6-K · Report of a foreign issuerJun 30, 2026Current reportSEC
6-K · Report of a foreign issuerJun 29, 2026Current reportSEC
6-K · Report of a foreign issuerJun 22, 2026Current reportSEC
6-K · Report of a foreign issuerMay 22, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
6-K · Report of a foreign issuerMay 15, 2026Current reportSEC
6-K · Report of a foreign issuerMay 7, 2026Current reportSEC
NT 20-FApr 30, 2026Explanation requestSEC
6-K · Report of a foreign issuerApr 29, 2026Current reportSEC
3 · Initial statement of ownershipMar 23, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 23, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 20, 2026Current reportSEC
6-K · Report of a foreign issuerMar 10, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 27, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 24, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 23, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 17, 2026Current reportSEC
6-K · Report of a foreign issuerJan 28, 2026Current reportSEC
6-K · Report of a foreign issuerJan 23, 2026Current reportSEC
6-K · Report of a foreign issuerJan 23, 2026Current reportSEC
6-K · Report of a foreign issuerJan 13, 2026Current reportSEC
6-K · Report of a foreign issuerJan 13, 2026Current reportSEC
6-K · Report of a foreign issuerDec 30, 2025Current reportSEC
6-K · Report of a foreign issuerDec 29, 2025Current reportSEC
6-K · Report of a foreign issuerDec 12, 2025Current reportSEC
6-K · Report of a foreign issuerDec 5, 2025Current reportSEC
6-K · Report of a foreign issuerOct 23, 2025Current reportSEC
6-K · Report of a foreign issuerJul 28, 2025Current reportSEC
6-K · Report of a foreign issuerJul 21, 2025Current reportSEC
6-K/A · Report of a foreign issuer, amendedJun 18, 2025Current reportSEC
6-K · Report of a foreign issuerJun 13, 2025Current reportSEC
20-F · Annual reportApr 30, 2025Annual reportSEC
6-K · Report of a foreign issuerApr 7, 2025Current reportSEC
6-K · Report of a foreign issuerMar 4, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 3, 2025Current reportSEC
6-K · Report of a foreign issuerDec 30, 2024Current reportSEC
6-K · Report of a foreign issuerDec 30, 2024Current reportSEC
6-K · Report of a foreign issuerNov 19, 2024Current reportSEC
6-K · Report of a foreign issuerNov 12, 2024Current reportSEC
6-K · Report of a foreign issuerOct 15, 2024Current reportSEC
6-K · Report of a foreign issuerAug 14, 2024Current reportSEC
6-K · Report of a foreign issuerJul 22, 2024Current reportSEC
6-K · Report of a foreign issuerJun 12, 2024Current reportSEC
6-K · Report of a foreign issuerJun 5, 2024Current reportSEC
6-K · Report of a foreign issuerMay 13, 2024Current reportSEC
6-K · Report of a foreign issuerApr 30, 2024Current reportSEC
20-F · Annual reportApr 30, 2024Annual reportSEC
6-K · Report of a foreign issuerApr 2, 2024Current reportSEC
6-K/A · Report of a foreign issuer, amendedMar 21, 2024Current reportSEC
6-K · Report of a foreign issuerMar 21, 2024Current reportSEC
6-K · Report of a foreign issuerMar 20, 2024Current reportSEC
6-K · Report of a foreign issuerNov 15, 2023Current reportSEC
6-K · Report of a foreign issuerOct 20, 2023Current reportSEC
6-K · Report of a foreign issuerAug 10, 2023Current reportSEC
6-K · Report of a foreign issuerMay 16, 2023Current reportSEC
20-F · Annual reportMar 22, 2023Annual reportSEC
6-K · Report of a foreign issuerMar 2, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 23, 2023Current reportSEC
6-K/A · Report of a foreign issuer, amendedFeb 1, 2023Current reportSEC
6-K · Report of a foreign issuerJan 20, 2023Current reportSEC
6-K · Report of a foreign issuerNov 29, 2022Current reportSEC
6-K · Report of a foreign issuerAug 24, 2022Current reportSEC
6-K · Report of a foreign issuerJun 1, 2022Current reportSEC
20-F · Annual reportMar 30, 2022Annual reportSEC
6-K · Report of a foreign issuerJan 26, 2022Current reportSEC
6-K · Report of a foreign issuerJan 19, 2022Current reportSEC
6-K · Report of a foreign issuerDec 16, 2021Current reportSEC
6-K · Report of a foreign issuerNov 24, 2021Current reportSEC
6-K · Report of a foreign issuerAug 24, 2021Current reportSEC
424B3 · ProspectusJun 9, 2021Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 8, 2021Other filingsSEC
POS AM · Amendment to an effective registrationJun 2, 2021Offer documentSEC
6-K · Report of a foreign issuerMay 19, 2021Current reportSEC
20-F/A · Annual report, amendedMay 19, 2021Annual reportSEC
6-K · Report of a foreign issuerMay 19, 2021Current reportSEC
6-K · Report of a foreign issuerApr 5, 2021Current reportSEC
6-K · Report of a foreign issuerMar 29, 2021Current reportSEC
20-F · Annual reportMar 15, 2021Annual reportSEC
6-K · Report of a foreign issuerFeb 22, 2021Current reportSEC
6-K · Report of a foreign issuerJan 7, 2021Current reportSEC
6-K · Report of a foreign issuerDec 31, 2020Current reportSEC
6-K · Report of a foreign issuerNov 25, 2020Current reportSEC
6-K · Report of a foreign issuerNov 12, 2020Current reportSEC
6-K · Report of a foreign issuerAug 24, 2020Current reportSEC
6-K · Report of a foreign issuerJul 7, 2020Current reportSEC
6-K · Report of a foreign issuerJun 30, 2020Current reportSEC
6-K · Report of a foreign issuerMay 27, 2020Current reportSEC
6-K · Report of a foreign issuerMay 26, 2020Current reportSEC
6-K · Report of a foreign issuerMay 26, 2020Current reportSEC
20-F · Annual reportMar 12, 2020Annual reportSEC
6-K · Report of a foreign issuerJan 29, 2020Current reportSEC
6-K · Report of a foreign issuerJan 22, 2020Current reportSEC
6-K/A · Report of a foreign issuer, amendedJan 13, 2020Current reportSEC
6-K · Report of a foreign issuerDec 18, 2019Current reportSEC
6-K · Report of a foreign issuerNov 27, 2019Current reportSEC
6-K · Report of a foreign issuerOct 31, 2019Current reportSEC
6-K · Report of a foreign issuerSep 4, 2019Current reportSEC
6-K · Report of a foreign issuerMay 30, 2019Current reportSEC
20-F · Annual reportMar 11, 2019Annual reportSEC
6-K · Report of a foreign issuerDec 27, 2018Current reportSEC
6-K · Report of a foreign issuerDec 20, 2018Current reportSEC
6-K · Report of a foreign issuerNov 15, 2018Current reportSEC
6-K · Report of a foreign issuerNov 8, 2018Current reportSEC
6-K · Report of a foreign issuerNov 1, 2018Current reportSEC
6-K · Report of a foreign issuerJul 24, 2018Current reportSEC
6-K · Report of a foreign issuerMay 29, 2018Current reportSEC
6-K · Report of a foreign issuerMay 22, 2018Current reportSEC
6-K · Report of a foreign issuerMay 15, 2018Current reportSEC
6-K · Report of a foreign issuerApr 10, 2018Current reportSEC
20-F · Annual reportMar 15, 2018Annual reportSEC
424B3 · ProspectusMar 7, 2018Offer documentSEC
EFFECT · Notice that a registration is effectiveMar 7, 2018Other filingsSEC
CORRESP · Letter to the SECMar 2, 2018Other filingsSEC
F-1/A · Registration statement, amendedFeb 28, 2018Offer documentSEC
F-1/A · Registration statement, amendedFeb 1, 2018Offer documentSEC
SC 13G/A · Big-stake notice, amendedJan 5, 2018Big-stake noticeSEC
6-K · Report of a foreign issuerDec 6, 2017Current reportSEC
6-K · Report of a foreign issuerNov 27, 2017Current reportSEC
6-K · Report of a foreign issuerOct 23, 2017Current reportSEC
6-K · Report of a foreign issuerSep 26, 2017Current reportSEC
6-K · Report of a foreign issuerSep 12, 2017Current reportSEC
6-K · Report of a foreign issuerAug 3, 2017Current reportSEC
6-K · Report of a foreign issuerJul 27, 2017Current reportSEC
6-K · Report of a foreign issuerJun 22, 2017Current reportSEC
6-K · Report of a foreign issuerJun 15, 2017Current reportSEC
6-K · Report of a foreign issuerApr 27, 2017Current reportSEC
6-K · Report of a foreign issuerApr 5, 2017Current reportSEC
6-K · Report of a foreign issuerApr 4, 2017Current reportSEC
20-F/A · Annual report, amendedApr 3, 2017Annual reportSEC
20-F · Annual reportMar 30, 2017Annual reportSEC
6-K · Report of a foreign issuerMar 30, 2017Current reportSEC
DMar 29, 2017Other filingsSEC
6-K · Report of a foreign issuerMar 22, 2017Current reportSEC
6-K · Report of a foreign issuerMar 9, 2017Current reportSEC
6-K · Report of a foreign issuerMar 7, 2017Current reportSEC
DMar 1, 2017Other filingsSEC
6-K · Report of a foreign issuerMar 1, 2017Current reportSEC
SC 13G · Big-stake noticeFeb 27, 2017Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 22, 2017Current reportSEC
424B5 · ProspectusFeb 22, 2017Offer documentSEC
6-K · Report of a foreign issuerFeb 17, 2017Current reportSEC
6-K · Report of a foreign issuerJan 25, 2017Current reportSEC
SC 13G/A · Big-stake notice, amendedJan 6, 2017Big-stake noticeSEC
6-K · Report of a foreign issuerJan 5, 2017Current reportSEC
6-K · Report of a foreign issuerJan 5, 2017Current reportSEC
6-K · Report of a foreign issuerDec 6, 2016Current reportSEC
6-K · Report of a foreign issuerNov 14, 2016Current reportSEC
CORRESP · Letter to the SECNov 7, 2016Other filingsSEC
F-1/A · Registration statement, amendedNov 7, 2016Offer documentSEC
6-K · Report of a foreign issuerSep 27, 2016Current reportSEC
6-K · Report of a foreign issuerSep 27, 2016Current reportSEC
6-K · Report of a foreign issuerSep 7, 2016Current reportSEC
6-K · Report of a foreign issuerAug 11, 2016Current reportSEC
6-K · Report of a foreign issuerJun 1, 2016Current reportSEC
20-F · Annual reportMar 31, 2016Annual reportSEC
6-K · Report of a foreign issuerMar 31, 2016Current reportSEC
6-K · Report of a foreign issuerMar 24, 2016Current reportSEC
6-K · Report of a foreign issuerMar 21, 2016Current reportSEC
6-K · Report of a foreign issuerMar 9, 2016Current reportSEC
6-K · Report of a foreign issuerMar 2, 2016Current reportSEC
6-K · Report of a foreign issuerFeb 22, 2016Current reportSEC
6-K · Report of a foreign issuerFeb 18, 2016Current reportSEC
6-K · Report of a foreign issuerFeb 10, 2016Current reportSEC
6-K · Report of a foreign issuerJan 27, 2016Current reportSEC
UPLOAD · Letter from the SECJan 26, 2016Other filingsSEC
6-K · Report of a foreign issuerJan 25, 2016Current reportSEC
6-K · Report of a foreign issuerJan 13, 2016Current reportSEC
SC 13G/A · Big-stake notice, amendedJan 12, 2016Big-stake noticeSEC
6-K · Report of a foreign issuerJan 11, 2016Current reportSEC
F-1 · Registration statementDec 31, 2015Offer documentSEC
6-K · Report of a foreign issuerDec 29, 2015Current reportSEC
6-K · Report of a foreign issuerDec 1, 2015Current reportSEC
6-K · Report of a foreign issuerOct 13, 2015Current reportSEC
6-K · Report of a foreign issuerSep 21, 2015Current reportSEC
6-K · Report of a foreign issuerSep 10, 2015Current reportSEC
6-K · Report of a foreign issuerSep 1, 2015Current reportSEC
6-K · Report of a foreign issuerSep 1, 2015Current reportSEC
6-K · Report of a foreign issuerAug 26, 2015Current reportSEC
6-K · Report of a foreign issuerJun 8, 2015Current reportSEC
20-F · Annual reportApr 28, 2015Annual reportSEC
6-K · Report of a foreign issuerApr 6, 2015Current reportSEC
SC 13G · Big-stake noticeApr 2, 2015Big-stake noticeSEC
424B5 · ProspectusApr 1, 2015Offer documentSEC
6-K · Report of a foreign issuerMar 31, 2015Current reportSEC
6-K · Report of a foreign issuerMar 25, 2015Current reportSEC
6-K · Report of a foreign issuerMar 16, 2015Current reportSEC
6-K · Report of a foreign issuerFeb 17, 2015Current reportSEC
6-K · Report of a foreign issuerDec 30, 2014Current reportSEC
6-K · Report of a foreign issuerDec 8, 2014Current reportSEC
6-K · Report of a foreign issuerDec 1, 2014Current reportSEC
6-K · Report of a foreign issuerDec 1, 2014Current reportSEC
6-K · Report of a foreign issuerNov 25, 2014Current reportSEC
6-K · Report of a foreign issuerNov 4, 2014Current reportSEC
6-K · Report of a foreign issuerNov 3, 2014Current reportSEC
6-K · Report of a foreign issuerOct 27, 2014Current reportSEC

This page holds 200 of 548 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from XTL Biopharmaceuticals Ltd.’s releases · as of Jan 29, 2026

Common shares
982,985,356
Fully diluted
982,985,356

Fully diluted

LineShares
Common shares982,985,356

Share count over time

CountShares
Nov 22, 2026982,985,356

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Citadel42,531US$102KSep 30, 2026
Rhumbline Advisers6,871US$16,488Sep 30, 2026
GAMMA Investing LLC3,436US$7,903Sep 30, 2026
UBS427US$983Sep 30, 2026
RBC100Sep 30, 2026

Funds

HolderSharesValueAs of
Fidelity Nasdaq Composite Index Fund2,225US$5,340May 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Kenneth J Zuerblis
Other companies: Stemline Therapeutics Inc (Director · Jan 28, 2013 – Jun 10, 2020 · Past); Savient Pharmaceuticals Inc (EVP, Chief Financial Officer · Sep 12, 2011 – Feb 1, 2012 · Past); Immunomedics Inc (Director · Feb 9, 2010 – Dec 7, 2011 · Past)
Director · Oct 10, 2008 – Oct 10, 2008 · Past
William James Kennedy
Other companies: TG Therapeutics, Inc. (Director · Apr 16, 2012 – Jun 17, 2020 · Past)
Director · Nov 4, 2008 – Nov 4, 2008 · Past
Dobroslav MelamedDirector · Since at least Nov 6, 2026
Doron TurgemanChief Executive Officer · Since at least Nov 6, 2026
Fain Osnat HillelDirector · Since at least Mar 18, 2026
Iris Shapira YalonDirector · Since at least Nov 6, 2026
Itay WeinsteinChief Financial Officer · Since at least Nov 6, 2026
Jonathan SchapiroDirector · Since at least Nov 6, 2026
Joshua LevineChief Executive Officer · Since at least Nov 6, 2026
Noam BandChief Executive Officer · Apr 7, 2025 – Nov 6, 2026 · Past
All 14 people
PersonSeat
Ossi Hillel FainDirector · Since at least Nov 6, 2026
Samuel RudmanDirector · Oct 10, 2008 – Oct 10, 2008 · Past
Shlomo ShalevChief Executive Officer · Since at least Apr 7, 2025
William KesslerDirector of Finance · Aug 21, 2007 – Aug 21, 2007 · Past

Open People

Log in to ask 6ix AI your own questions about XTL Biopharmaceuticals Ltd.